
Hepatectomy for Noncolorectal Non-Neuroendocrine Metastatic Cancer: A Multi-Institutional Analysis

Ryan T Groeschl, MD, Ido Nachmany, MD, Jennifer L Steel, PhD, Srinevas K Reddy, MD, Evan S Glazer, MD, Mechteld C de Jong, MD, Timothy M Pawlik, MD, MPH, FACS, David A Geller, MD, FACS, Allan Tsung, MD, FACS, J Wallis Marsh, MD, FACS, Bryan M Clary, MD, FACS, Steven A Curley, MD, FACS, T Clark Gamblin, MD, MS, FACS

BACKGROUND: Although hepatic metastasectomy is well established for colorectal and neuroendocrine cancer, the approach to hepatic metastases from other sites is not well defined. We sought to examine the management of noncolorectal non-neuroendocrine liver metastases.

STUDY DESIGN: A retrospective review from 4 major liver centers identified patients who underwent liver resection for noncolorectal non-neuroendocrine metastases between 1990 and 2009. The Kaplan-Meier method was used to analyze survival, and Cox regression models were used to examine prognostic variables.

RESULTS: There were 420 patients available for analysis. Breast cancer (n = 115; 27%) was the most common primary malignancy, followed by sarcoma (n = 98; 23%), and genitourinary cancers (n = 92; 22%). Crude postoperative morbidity and mortality rates were 20% and 2%, respectively. Overall median survival was 49 months, and 1, 3, and 5-year Kaplan-Meier survival rates were 73%, 50%, and 31%. Survival was not significantly different between the various primary tumor types. Recurrent disease was found after hepatectomy in 66% of patients. In multivariable models, lymphovascular invasion (p = 0.05) and metastases ≥ 5 cm (p = 0.04) were independent predictors of poorer survival. Median survival was shorter for resections performed between 1990 and 1999 (n = 101, 32 months) when compared with resections between 2000 and 2009 (n = 319, 66 months; p = 0.003).

CONCLUSIONS: Hepatic metastasectomy for noncolorectal non-neuroendocrine cancers is safe and feasible in selected patients. Lymphovascular invasion and metastases ≥ 5 cm were found to be associated with poorer survival. Patients undergoing metastasectomy in more recent years appear to be surviving longer, however, the reasons for this are not conclusively determined. (J Am Coll Surg 2012;214:769–777. © 2012 by the American College of Surgeons)

CME questions for this article available at <http://jacscme.facs.org>

Disclosure Information: Authors have nothing to disclose. Timothy J Eberlein, Editor-in-Chief, has nothing to disclose.

Presented at the 64th Society of Surgical Oncology Annual Cancer Symposium, San Antonio, TX, March 2011.

Received October 4, 2011; Revised December 9, 2011; Accepted December 28, 2011.

From the Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee, WI (Groeschl, Gamblin), Department of Surgery, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (Nachmany), Liver Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA (Steel, Reddy, Geller, Tsung, Marsh), Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX (Glazer, Curley), Division of Surgical Oncology, Johns Hopkins University, Baltimore, MD (de Jong, Pawlik), and Division of Surgical Oncology, Duke University Medical Center, Durham, NC (Clary).

Correspondence address: T Clark Gamblin, MD, MS, FACS, Division of Surgical Oncology, Medical College of Wisconsin, 9200 W Wisconsin Ave, Suite 3510, Milwaukee, WI 53226. email: tcgamblin@mcw.edu

The liver is a primary site of metastasis for tumors originating at many sites. Metastatic colorectal cancer is the most common entity, with the portal circulation and lymphatic channels acting as the conduit for spread. Better understanding of tumor biology, improved techniques for liver resection,^{1,2} and multidisciplinary treatments have led to new algorithms for managing metastatic disease in the liver. For selected patients, surgical resection of colorectal liver metastases has shown 5-year survival rates as high as 40% to 71%.³⁻⁷ Numerous studies have shown that surgical resection is also a safe and appropriate intervention for hepatic neuroendocrine metastases.⁸⁻¹¹ Approaches and outcomes for hepatectomy in patients with liver metastases from noncolorectal non-neuroendocrine tumors, however, are not well defined.

Recent publications have suggested that hepatectomy for noncolorectal non-neuroendocrine liver metastases (NCNNLM) is feasible and safe.¹²⁻¹⁸ Reports to date are largely confined to single-center studies. A better under-

Abbreviations and Acronyms

DFS	= disease-free survival
LVI	= lymphovascular invasion
NCNNLM	= noncolorectal non-neuroendocrine liver metastases
OS	= overall survival

standing of the potential benefit of surgical resection for these tumors is needed. Our objective was to assess the safety and outcomes of patients undergoing liver resection for NCNNLM at high-volume hepatobiliary centers.

METHODS

We examined patients who underwent liver resection between 1990 and 2009 for NCNNLM at 4 major hepatobiliary centers in the United States (Duke University Medical Center, Durham, NC; Johns Hopkins Hospital, Baltimore, MD; MD Anderson Cancer Center, Houston, TX; University of Pittsburgh Medical Center, Pittsburgh, PA). This study was approved by the Institutional Review Boards of the respective institutions. Patients with direct hepatic invasion by an extrahepatic primary tumor were excluded from analysis. Patients were evaluated by a multidisciplinary team and preoperative and/or postoperative systemic therapy was uniformly considered. Patients who showed progression of disease during preoperative systemic therapy were typically not offered hepatectomy. Resectable liver lesions are those for which complete resection is anticipated based on preoperative imaging, adequate vascular flow and biliary drainage are spared, and the size of the future liver remnant will be adequate ($\geq 20\%$ of total estimated liver volume).

Standard demographic and clinicopathologic data were collected for each patient, including sex, age, and race. Information about the original cancer diagnosis and adjuvant therapy was also collected, along with preoperative serum tumor markers. The number, size, and laterality of hepatic metastases were assessed. Perioperative details included use of laparoscopy, extent of hepatic resection, use of Pringle maneuver, operative time, blood loss, and mortality. The resected specimen was pathologically examined for margin status, lymph nodes, and lymphovascular invasion (LVI). For those patients in whom recurrent disease developed, disease-free intervals were calculated. If a liver metastasis occurred within 6 months of primary tumor resection, it was categorized as synchronous. Resection of ≥ 4 segments was considered a major hepatectomy.¹⁹ Complications were reported based on the Clavien criteria.²⁰ Grade II or higher complications were included for analy-

sis. Hepatectomy-specific complications included bleeding, bile leak, abscess, wound infections, and liver failure.

Patients who had residual disease after liver resection (R1 or R2 resections) were excluded from disease-free survival (DFS) analysis. Intraoperative mortality cases were excluded from overall survival (OS) and DFS analyses. Aside from that exception, OS reflects death from any cause. Deaths were ascertained by clinic and hospital records, public records, and the Social Security Death Index. Lengths of OS and DFS were calculated from the date of liver resection.

Variables that might be associated with survival outcomes in our cohort (based on previous literature) were identified for inclusion in the analysis a priori. These included age, sex, primary tumor type, major resection, synchronous lesions, additional extrahepatic metastatic disease, number of metastases, size of largest metastasis, margin status, lymphovascular invasion, use of adjuvant therapies, and the decade the resection was performed (1990–1999 vs 2000–2009). Descriptive statistics were calculated for all variables and the normality of the data examined. Chi-square and Mann-Whitney *U*-tests were used to test between-group differences on demographic and clinicopathologic parameters by primary tumor site. Multiple comparisons were accounted for by Bonferroni correction. Survival curves were generated using the Kaplan-Meier method.²¹ Variables with univariate significance at a level of $p \leq 0.20$ were entered into a Cox regression multivariable analysis. Significance was set at $\alpha = 0.05$. Statistical analyses were performed using PASW statistical software (version 18; PASW Inc.).

RESULTS

Patient, tumor, and operative characteristics

We identified 420 consecutive patients who had undergone liver resection for NCNNLM, of whom 303 (72.1%) were female. Median age at time of liver resection was 55 (interquartile range 45 to 64) years. The number of operations performed annually is shown in [Figure 1](#). There were 101 hepatectomies performed between 1990 and 1999, and there were 319 hepatectomies performed between 2000 and 2009. Breast cancer was the most common malignant pathology. The other primary tumor types and selected characteristics are shown in [Table 1](#). Primary tumors were resected in 399 of 420 (95.0%) patients. The remaining 21 patients had complete responses to chemoradiation of their primary tumors and did not require resection.

Liver metastases were synchronous in 109 of 419 (26.0%) patients, and unilateral in 134 of 192 (70.0%) patients. Patients with melanoma were more likely to have metachronous development of liver metastases (93.5%) as




Figure 1. Annual number of liver resections for noncolorectal non-neuroendocrine liver metastases at 4 major hepatobiliary centers in the United States from 1990 to 2009 (n = 420).

compared with other histologies (72.4%; $p = 0.01$). Extrahepatic metastases were resected in 77 of 362 (21.3%) patients. R0 liver resections were achieved in 340 of 391 (87.0%) patients. Radiofrequency ablation was performed on additional liver metastases in 36 of 339 (10.6%) patients. In 57 of 396 (14.4%) patients, liver metastases were diagnosed before resection of the primary tumor. For the remaining patients, the mean time between resection of the primary tumor and diagnosis of liver metastases was 43 months (range 0 to 312 months). This includes 42 patients who had liver metastases diagnosed during surgery for their primary cancer. Twenty of the 101 patients in the 1990–1999 cohort had liver metastases diagnosed intraoperatively during surgery for their primary cancer, for a rate of 19.8%. In the 2000–2009 cohort, there were only 22 such intraoperative diagnoses among 319 patients, for a rate of 6.9%.

The vast majority of operations were open resections. Only 13 cases were completed laparoscopically, and 4 of these were hand assisted. Major hepatectomies were per-

formed in 204 of 419 (48.7%) patients, and were more commonly performed for breast and melanoma compared with other primaries. In total, 326 patients were treated with chemotherapy: 275 of 414 (66.4%) received chemotherapy before hepatectomy and 208 of 399 (52.1%) received chemotherapy after hepatectomy. Transarterial chemoembolization was performed preoperatively in 1 patient and postoperatively in 2 patients. Radiation therapy was performed in 15 of 405 (3.7%) patients after hepatectomy. Eight patients underwent multiple liver resections for recurrent hepatic disease.

Outcomes

Complications occurred in 84 of 420 (20.0%) patients. Eight (1.9%) patients died within 60 days, 4 of which were intraoperative deaths. Postoperative bleeding occurred in 6 (1.4%) patients, bile leak in 6 (1.4%), liver failure in 1 (0.2%), intra-abdominal abscess in 11 (2.6%), and wound infections in 5 (1.2%).

Table 2 summarizes long-term patient follow-up and outcomes. Median follow-up for all patients was 30 months. Median OS and DFS were 49 months and 23 months, respectively. Figure 2 displays corresponding survival curves. At the time of analysis, 211 (50.2%) patients were still alive and 93 (22.1%) had no evidence of recurrent disease.

Table 3 shows the results of our univariate Kaplan-Meier survival analysis. In unadjusted models, both LVI and size of the largest metastasis were associated with poorer survival (Fig. 3). In a multivariable analysis controlling for age, synchronicity, R0 resections, and use of adjuvant chemotherapy; LVI (hazard ratio = 1.81; $p = 0.05$) and metastases ≥ 5 cm (hazard ratio = 1.39, $p = 0.04$) remained significant predictors of poorer survival (Table 4).

Patients who underwent hepatectomy from 1990 to 1999 had a median survival of 32 months, and patients with resections from 2000 to 2009 had a median sur-

Table 1. Characteristics of 420 Patients Undergoing Hepatic Metastasectomy from 1990 to 2009

Variable	Breast		Sarcoma		Genitourinary*		Melanoma		Other†	
	n	%	n	%	n	%	n	%	n	%
Patients	115	27	98	23	92	22	31	7	84	20
Preoperative chemotherapy	100/114	88	54/97	56	62/90	69	14/31	45	45/82	55
Postoperative chemotherapy	71/109	65	55/94	59	43/89	48	8/30	27	31/77	40
Synchronous	24/114	21	25/98	26	23/92	25	2/31	6	35/84	42
Major resection	68/114	60	45/98	46	36/92	39	17/31	55	38/84	45
R0 resection	92/107	86	80/87	92	73/85	86	28/29	97	67/83	81

*There were 26 patients with renal cell carcinoma included in this category.

†This category includes 24 squamous cell carcinomas, 14 gastrointestinal stromal tumors, 13 gastroesophageal adenocarcinomas, 11 pancreaticobiliary cancers, 8 lung cancers, 5 adrenocortical carcinomas, 2 adenocarcinomas of unknown primary, a medullary thyroid cancer, a Hürthle cell cancer, a perivascular epithelioid cell tumor, a primary peritoneal cancer, a mesothelioma, a thymoma, and a paraganglioma.

Table 2. Recurrence and Kaplan-Meier Survival Analyses after Metastasectomy

	Breast (n = 115)	Sarcoma (n = 98)	GU (n = 92)	Melanoma (n = 31)	Other (n = 84)	Overall (n = 420)
Median follow-up, mo	31	32	23	35	24	30
Median OS, mo	52	72	46	39	39	49
1-year OS, %	79	82	66	57	69	73
3-year OS, %	52	60	48	36	46	50
5-year OS, %	27	32	32	36	30	31
Median DFS, mo	22	31	28	12	19	23
Recurrence,* n (%)	66/103 (64)	55/89 (62)	47/77 (61)	21/29 (72)	53/66 (80)	242/364 (66)
Local/regional	43/103 (42)	32/89 (36)	26/77 (34)	9/29 (31)	32/66 (48)	142/364 (39)
Distant	48/103 (47)	42/89 (47)	41/77 (53)	17/29 (59)	35/66 (53)	183/364 (50)

*Some patients had both local/regional recurrence and distant recurrence. DFS, disease-free survival; GU, genitourinary; OS, overall survival.

vival of 66 months ($p = 0.003$). The respective 1, 3, and 5-year survivals were 61%, 39%, and 18% for those resections in the earlier decade, and 77%, 55%, and 38% in the latter decade. A post hoc comparison (using Bonferroni corrections) of demographic and clinical variables was performed to study this difference in survival between decades. These decade cohorts were similar with respect to age, sex, race, primary tumor type, synchronicity, tumor size, number of metastases, extrahepatic disease, LVI, and margin status. Operations from 2000 to 2009 involved less blood loss (median 250 mL; interquartile range 100 to 500 mL) as compared with operations from 1990 to 1999 (median 500 mL; interquartile range 200 to 800 mL; $p = 0.01$). In the latter decade, more patients were treated with preoperative chemotherapy (227 of 314 [72%] vs 48 of 100 [48%]; $p = 0.001$) and postoperative chemotherapy (178 of 305 [58%] vs 30 of 94 [32%]; $p = 0.001$).

After hepatectomy, recurrence occurred in 242 of 364 (66.5%) patients. Isolated hepatic recurrence occurred in 59 (16.2%) patients and isolated distant recurrence occurred in 100 (27.5%). Both distant and hepatic recurrence developed in 83 (22.8%) patients. Recurrence by primary tumor type is shown in Table 5. The various primary tumor types did not show significant differences in their overall recurrence rates, hepatic recurrences, bone metastases, or lung metastases. Brain metastases were more common in the breast cancer cohort.

Observations on patients undergoing multiple liver resections

After their first hepatectomy, recurrent disease in the liver developed in 142 of 364 (39.0%) patients. Seven of these patients underwent a second liver resection for subsequent hepatic recurrence, and another patient underwent a total of 3 liver resections for multiple hepatic recurrences. The range of time between these hepatectomies was 5 to 55 months (median 35 months). The timing of each resection

for these 8 patients is summarized in Table 6. Interestingly, each of these 8 patients was still alive at the end of the study period, with a median follow-up of 6 years after their last hepatectomy.

DISCUSSION

Hepatic resection for colorectal liver metastases has been established as a safe practice with favorable outcomes in carefully selected patients. Because these metastases presumably spread to the liver via portal circulation and/or abdominal lymphatic channels, the extent of malignancy is often confined to the abdomen, making hepatectomy intuitively more effective for controlling the extent of disease. Likewise, liver metastases from neuroendocrine tumors can be resected safely with favorable outcomes. For cancers of other primary sites (eg, breast cancer), spread to the liver seems only possible through systemic hematogenous dissemination. Historically, there has been concern that hepatectomy is less beneficial for these patients, but this notion has been challenged by several publications during the last 2 decades. Because of the lack of data supporting other treatment modalities, the improved capabilities in preoperative workup, and the modern safety of liver surgery at tertiary centers, hepatectomy for NCNNLM is gaining enthusiasm.

Most published studies of hepatectomy for NCNNLM have only a small number of patients, which can limit the power of the observations and conclusions drawn from them. Other studies include patients from low-volume centers, which can also influence outcomes. The present study includes 420 patients from only high-volume liver centers in the United States. Table 7 shows our study in comparison with other publications specifically addressing hepatectomy for NCNNLM. When reported in the larger studies, the median survival ranged from 27 to 44 months.^{15,18,22-24} Median survival in this series was 49 months, which is the longest among the published series of >100 patients.




Figure 2. (A) Overall survival by primary tumor type. (B) Disease-free survival by primary tumor type. GU, genitourinary; MM, melanoma.


Hepatic resection for breast cancer metastases has been associated with median and 5-year survivals of 25 to 57 months and 18% to 61%, respectively.²⁵ Other reports have shown favorable survival for metastasectomy of breast and genitourinary cancers, which were well represented in our cohort.^{15,22,23,26} Median survivals of our breast and genitourinary cohorts were 52 and 46 months, respectively. Our subset of sarcoma patients had median, 1, 3, and

Table 3. Univariate Analysis of Factors Associated with Survival after Liver Resection of Noncolorectal Non-Neuroendocrine Metastases


Variable	Median OS (mo)	95% CI	Log rank chi-square	p Value
Age, y			3.5	0.06
Younger than 65	52	38–66		
65 or older	44	31–57		
Sex			0.04	0.85
Female	49	34–64		
Male	46	21–71		
Tumor type			4.04	0.40
Breast	52	36–68		
Sarcoma	72	30–114		
Genitourinary	46	18–74		
Melanoma	39	14–74		
Other	39	22–56		
Major resection			0.90	0.34
Yes	46	35–57		
No	50	26–74		
Synchronous			2.43	0.12
Yes	61	—		
No	122	96–148		
Extrahepatic metastatic disease			0.03	0.88
Yes	48	24–72		
No	49	35–63		
No. of metastases			0.023	0.88
1	51	33–69		
≥2	46	31–62		
Size of largest metastasis, cm			9.2	0.002
<5	66	46–86		
≥5	37	29–46		
R0 resection			2.42	0.12
Yes	52	38–66		
No	37	30–44		
Lymphovascular invasion			4.37	0.04
Yes	25	12–37		
No	52	39–65		
Neoadjuvant chemotherapy			0.75	0.39
Yes	52	36–68		
No	46	27–65		
Adjuvant chemotherapy			2.68	0.10
Yes	58	39–77		
No	43	30–56		

OS, overall survival.

5-year survivals of 72 months, 82%, 60%, and 32%, respectively. Comparably, 56 patients underwent sarcoma metastasectomy reported by DeMatteo and colleagues²⁷ with median, 1, 3, and 5-year survivals of 39 months, 88%,



A



B

Figure 3. (A) Overall survival by presence of lymphovascular invasion. (B) Overall survival by size of largest metastasis.

50%, and 30%, respectively. Mariani and colleagues²⁸ study of 255 patients who underwent hepatic metastasectomy for melanoma showed a median survival of only 14 months compared with the median survival of 39 months in our series of 31 patients.

Patient selection is critical to improving long-term outcomes for hepatic metastasectomy. The body of literature

Table 4. Cox Proportional Hazards Regression Analysis of Factors Associated with Survival after Liver Resection of Noncolorectal Non-Neuroendocrine Metastases

Variable	Hazard ratio	95% CI	p Value
Age, y			0.12
Younger than 65	1	—	
65 or older	1.33	0.93–1.89	
Synchronous			0.79
No	1	—	
Yes	1.05	0.67–1.36	
Size of largest metastasis, cm			0.04
<5	1	—	
≥5	1.39	1.02–1.91	
R0 resection			0.17
No	1	—	
Yes	0.75	0.49–1.14	
Lymphovascular invasion			0.05
No	1	—	
Yes	1.81	1.01–3.29	
Adjuvant chemotherapy			0.18
No	1	—	
Yes	0.81	0.60–1.10	

on this topic is growing and, despite its heterogeneity, certain trends are emerging. Several authors' works have suggested a worse prognosis for esophageal and gastric adenocarcinoma metastases.^{17,22,29,30} Our series included only 13 (3.1%) such patients, with similar results. OS of our entire cohort likely benefits from the conscious exclusion of these types of cancers by our multidisciplinary teams. Although a longer interval between resection of the primary tumor and development of metastases is sometimes considered a surrogate for favorable tumor biology,^{16,22,23,30–32} our study did not find a survival benefit for longer intervals. R0 resection^{23,30,31} and the presence of extrahepatic nodes²⁴ have also been implicated in survival for resection of NCNNLM. In our study, neither of these factors impacted survival to a statistically significant degree. Our cohort showed that LVI was associated with shorter survival, which has not been reported previously. Other publications have found that metastasectomy for larger lesions is associated with a poorer prognosis, and our data support this finding.^{24,30}

Although stage IV adrenocortical cancer is associated with a dismal prognosis ($\leq 15\%$ 5-year survival),³³ our series of 5 patients who underwent resections for adrenocortical metastases had acceptable outcomes. Three patients died at approximately 3, 5, and 10 years after their liver resections. There are 2 patients still alive 9 and 13 years after their metastasectomies. Adam and colleagues²² reported 28 cases of liver resection for adrenocortical metas-

Table 5. Percentage of Patients in Whom Recurrence Develops after Metastasectomy, by Primary Tumor Type*

	Primary cancer histology									
	Breast (n = 103)		Sarcoma (n = 89)		Genitourinary (n = 77)		Melanoma (n = 29)		Other (n = 66)	
	n	%	n	%	n	%	n	%	n	%
Any recurrence	66	64	55	62	47	61	21	72	53	80
Site of recurrence										
Liver	43	42	32	36	26	34	9	31	32	48
Lung	19	18	20	22	13	17	10	34	21	32
Bone	15	15	6	7	6	8	2	7	4	6
Brain	11	11	2	2	1	1	0		1	2
Abdominal	13	13	23	26	27	35	7	24	11	17
Other site	4	4	5	6	5	6	2	7	3	4

*Many patients recurred in more than one site. Percentages shown represent the frequency of recurrence in a given site, not the proportion of recurrences that occur in those sites, so columns do not add to 100%.

tases with a 5-year survival of 66%. Patients with adrenocortical liver metastases who appear to have favorable tumor biology should be given careful consideration for hepatic resection.

A multidisciplinary approach provides an important tool for cancer patients. Neoadjuvant or adjuvant therapies were used in 338 (80.5%) of our study population, with many patients receiving more than one type of therapy. Patients who received any chemotherapy after hepatectomy lived longer, although this did not reach statistical significance. A weakness of such a binary analysis is that it includes patients who did not complete what might be considered a full course of therapy. This would cause us to underestimate the potential impact that a completed course of therapy might have on recurrence or survival. This study was not designed to evaluate the effectiveness of other liver-directed therapies, such as ablation. Previous reports about colorectal liver metastases showed that outcomes for ablated lesions are inferior to outcomes for surgical resection.³

Our patients who underwent repeat hepatectomy represent an intriguing group. All 8 patients were alive at the end

of the study, some more than 9 years out from their first liver resection. Although recurrence typically portends a worse prognosis, these patients again highlight the importance of thoughtful selectivity and advances in the surgical techniques of liver resection. Other authors have also noted that repeat hepatectomy for NCCNLM is associated with improved survival.²² Given these findings, patients with resectable hepatic recurrence should be considered for repeat hepatectomy.

There are several limitations of this retrospective review. We lack a control group and cannot make conclusions about the effectiveness of surgery in comparison with other treatments. Our cohort is also heterogeneous, composed of patients with metastases from several different primary tumors. Although some cancers are well represented, their malignant behavior might not be generalizable to less common primaries. We included patients during a 19-year span, and certainly during those years there have been substantial changes to adjuvant therapies, operative techniques, and cross-sectional imaging. Operative blood loss decreased over time in our study. As chemotherapeutic regimens evolve for cancers that metastasize to the liver, they

Table 6. Eight Patients Who Underwent Multiple Hepatectomies for Recurrent Disease in the Liver

Patient	Primary tumor histology	Primary tumor diagnosed	Primary tumor resected	First liver metastasis diagnosed	First liver metastasis resected	Second liver metastasis diagnosed	Second liver metastasis resected	Last follow-up
A*	Breast	Dec 1994	Jan 1995	Aug 1996	Feb 2001	Apr 2004	Jun 2004	Aug 2008
B	Melanoma	Jan 1995	Jan 1995	Nov 2003	Apr 2004	Sep 2004	Sep 2004	Oct 2009
C	Sarcoma	Feb 1997	Feb 1997	Aug 2000	Dec 2002	Aug 2003	Jun 2004	Jun 2009
D	GIST	May 1998	May 1998	Oct 1999	Oct 1999	Jan 2000	Jun 2002	Nov 2008
E	Sarcoma	Sep 1999	Sep 1999	Feb 2004	Oct 2004	Feb 2008	May 2009	Jul 2009
F	Adrenal	Jun 2000	Aug 2000	Jun 2000	Sep 2000	Dec 2002	Oct 2004	Sep 2009
G	Sarcoma	Feb 2002	Aug 2002	Jan 2002	Jun 2004	—	Sep 2007	Jun 2009
H	Breast	Jun 2005	Jun 2005	Jun 2005	Apr 2006	Nov 2008	Mar 2009	Jul 2009

*Patient A was diagnosed with a third hepatic tumor in July 2005 and underwent resection the same month. She is still alive. GIST, gastrointestinal stromal tumor.

Table 7. Publications Describing Patients Undergoing Resection for Noncolorectal Non-Neuroendocrine Liver Metastases

First author	Year	n	Operative mortality, %	Operative morbidity, %	5-year survival, %
Harrison ⁴⁰	1997	96	0	NR	37
Hemming ⁴¹	2000	37	0	NR	45
Laurent ⁴²	2001	39	0	8	35
Takada ⁴³	2001	14	7	NR	NR
Yamada ⁴⁴	2001	33	9	21	12
Karavias ⁴⁵	2002	18	0	11	NR
Cordera ²⁹	2005	64	2	7	30
Ercolani ¹⁵	2005	142	0	21	34
Weitz ¹⁶	2005	141	0	33	NR
Adam ²²	2006	1452	2	22	36
Teo ⁴⁶	2006	18	0	0	NR
Lendoire ²³	2007	106	2	NR	19
Reddy ¹⁸	2007	82*	4	30	37
O'Rourke ²⁴	2008	102	1	21	39
Ercolani ³⁰	2009	134	3	23	40
Lehner ²⁶	2009	242	2	21	28
Groeschl [†]	2011	420	2	20	31

*These 82 patients represent the NCNNLM subset of the entire study cohort.

†Represents the current article.

NR, not reported.

are affording patients longer survival.³⁴⁻³⁶ In the past 2 decades, there has also been an increase in diagnostic accuracy for liver tumors with multidetector CT and MRI.^{37,38} This higher quality cross-sectional imaging, along with other diagnostic tools, such as positron emission tomography, might have allowed for better patient selection in the later decade. In many ways, the longer survival in our 2000-2009 cohort mimics the recent improvement noted with patients undergoing resection for colorectal liver metastases.³⁹

CONCLUSIONS

In summary, NCNNLM represent an advanced stage of cancer that, when appropriately selected, can be resected safely and with reasonable survival outcomes. Hepatectomy should be considered as a tool within the broader scope of a multidisciplinary approach, especially for metastases <5 cm. Judicious use of chemotherapy in conjunction with surgery can further improve survival. In addition to the multiple prognostic factors that have already been identified in the literature, we found that microscopic evidence of LVI was associated with poorer outcomes. More investigation into this field is warranted to find the comparative benefit of surgery, chemotherapy, chemoembolization, radiation, and other adjunct therapies.

Author Contributions

Study conception and design: Groeschl, Nachmany, Steel, Gamblin

Acquisition of data: Nachmany, Reddy, Glazer, de Jong
 Analysis and interpretation of data: Groeschl, Nachmany, Steel, Reddy, Glazer, de Jong, Pawlik, Geller, Tsung, Marsh, Clary, Curley, Gamblin
 Drafting of manuscript: Groeschl, Nachmany, Steel, Reddy, Glazer, de Jong, Pawlik, Geller, Tsung, Marsh, Clary, Curley, Gamblin
 Critical revision: Groeschl, Nachmany, Steel, Reddy, Glazer, de Jong, Pawlik, Geller, Tsung, Marsh, Clary, Curley, Gamblin

REFERENCES

1. Belghiti J, Hiramatsu K, Benoist S, et al. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. *J Am Coll Surg* 2000;191:38-46.
2. Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. *Ann Surg* 2002;236:397-406.
3. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. *Ann Surg* 2004;239:818-825.
4. Aloia TA, Vauthey JN, Loyer EM, et al. Solitary colorectal liver metastasis: resection determines outcome. *Arch Surg* 2006;141:460-466.
5. Taniai N, Yoshida H, Mamada Y, et al. Outcome of surgical treatment of synchronous liver metastases from colorectal cancer. *J Nihon Med Sch*. 2006;73:82-88.
6. Tomizawa N, Ohwada S, Ogawa T, et al. Factors affecting the

- prognosis of anatomical liver resection for liver metastases from colorectal cancer. *Hepatogastroenterology* 2006;53:89–93.
7. Wei AC, Greig PD, Grant D, et al. Survival after hepatic resection for colorectal metastases: a 10-year experience. *Ann Surg Oncol* 2006;13:668–676.
 8. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? *J Am Coll Surg* 2000;190:432–445.
 9. Chen H, Hardacre JM, Uzar A, et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? *J Am Coll Surg* 1998;187:88–92.
 10. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. *J Am Coll Surg* 2003;197:29–37.
 11. Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. *Ann Surg Oncol* 2010;17:3129–3136.
 12. Buell JF, Rosen S, Yoshida A, et al. Hepatic resection: effective treatment for primary and secondary tumors. *Surgery* 2000;128:686–693.
 13. Earle SA, Perez EA, Gutierrez JC, et al. Hepatectomy enables prolonged survival in select patients with isolated noncolorectal liver metastasis. *J Am Coll Surg* 2006;203:436–446.
 14. Elias D, Cavalcanti de Albuquerque A, Eggenspieler P, et al. Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. *J Am Coll Surg* 1998;187:487–493.
 15. Ercolani G, Grazi GL, Ravaioli M, et al. The role of liver resections for noncolorectal, nonneuroendocrine metastases: experience with 142 observed cases. *Ann Surg Oncol* 2005;12:459–466.
 16. Weitz J, Blumgart LH, Fong Y, et al. Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma. *Ann Surg* 2005;241:269–276.
 17. Yedibela S, Gohl J, Graz V, et al. Changes in indication and results after resection of hepatic metastases from noncolorectal primary tumors: a single-institutional review. *Ann Surg Oncol* 2005;12:778–785.
 18. Reddy SK, Barbas AS, Marroquin CE, et al. Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis. *J Am Coll Surg* 2007;204:372–382.
 19. Reddy SK, Barbas AS, Turley RS, et al. A standard definition of major hepatectomy: resection of four or more liver segments. *HPB (Oxford)* 2011;13:494–502.
 20. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004;240:205–213.
 21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 1958;53:457–481.
 22. Adam R, Chiche L, Aloia T, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. *Ann Surg* 2006;244:524–535.
 23. Lendoire J, Moro M, Andriani O, et al. Liver resection for noncolorectal, non-neuroendocrine metastases: analysis of a multicenter study from Argentina. *HPB (Oxford)* 2007;9:435–439.
 24. O'Rourke TR, Tekkis P, Yeung S, et al. Long-term results of liver resection for non-colorectal, non-neuroendocrine metastases. *Ann Surg Oncol* 2008;15:207–218.
 25. Elias D, Di Pietroantonio D. Surgery for liver metastases from breast cancer. *HPB (Oxford)* 2006;8:97–99.
 26. Lehner F, Ramackers W, Bektas H, et al. Liver resection for non-colorectal, non-neuroendocrine liver metastases—is hepatic resection justified as part of the oncosurgical treatment? *Zentralbl Chir* 2009;134:430–436.
 27. DeMatteo RP, Shah A, Fong Y, et al. Results of hepatic resection for sarcoma metastatic to liver. *Ann Surg* 2001;234:540–547.
 28. Mariani P, Piperno-Neumann S, Servois V, et al. Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. *Eur J Surg Oncol* 2009;35:1192–1197.
 29. Cordera F, Rea DJ, Rodriguez-Davalos M, et al. Hepatic resection for noncolorectal, nonneuroendocrine metastases. *J Gastrointest Surg* 2005;9:1361–1370.
 30. Ercolani G, Vetrone G, Grazi GL, et al. The role of liver surgery in the treatment of non-colorectal non-neuroendocrine metastases (NCRNNE). Analysis of 134 resected patients. *Minerva Chir* 2009;64:551–558.
 31. Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. *Ann Surg* 1990;211:277–287.
 32. Di Carlo I. Liver surgery for noncolorectal nonneuroendocrine metastases. *HPB (Oxford)* 2006;8:83–84.
 33. Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. *Best Pract Res Clin Endocrinol Metab* 2009;23:273–289.
 34. Fournier MN. Approved agents for metastatic breast cancer. *Semin Oncol* 2011;38[Suppl 2]:S3–S10.
 35. McRee AJ, Goldberg RM. Optimal management of metastatic colorectal cancer: current status. *Drugs* 2011;71:869–884.
 36. Peterson C. Drug therapy of cancer. *Eur J Clin Pharmacol* 2011;67:437–447.
 37. Schwartz L, Brody L, Brown K, et al. Prospective, blinded comparison of helical CT and CT arterial portography in the assessment of hepatic metastasis from colorectal carcinoma. *World J Surg* 2006;30:1892–1899.
 38. van Kessel CS, van Leeuwen MS, van den Bosch MA, et al. Accuracy of multislice liver CT and MRI for preoperative assessment of colorectal liver metastases after neoadjuvant chemotherapy. *Dig Surg* 2011;28:36–43.
 39. Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. *J Gastrointest Surg* 2007;11:1057–1077.
 40. Harrison LE, Brennan MF, Newman E, et al. Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients. *Surgery* 1997;121:625–632.
 41. Hemming AW, Sielaff TD, Gallinger S, et al. Hepatic resection of noncolorectal nonneuroendocrine metastases. *Liver Transpl* 2000;6:97–101.
 42. Laurent C, Rullier E, Feyler A, et al. Resection of noncolorectal and nonneuroendocrine liver metastases: late metastases are the only chance of cure. *World J Surg* 2001;25:1532–1536.
 43. Takada Y, Otsuka M, Seino K, et al. Hepatic resection for metastatic tumors from noncolorectal carcinoma. *Hepatogastroenterology* 2001;48:83–86.
 44. Yamada H, Katoh H, Kondo S, et al. Hepatectomy for metastases from non-colorectal and non-neuroendocrine tumor. *Anticancer Res* 2001;21:4159–4162.
 45. Karavias DD, Tepetes K, Karatzas T, et al. Liver resection for metastatic non-colorectal non-neuroendocrine hepatic neoplasms. *Eur J Surg Oncol* 2002;28:135–139.
 46. Teo MC, Tan YM, Chung AY, et al. Metastectomy for noncolorectal, non-neuroendocrine liver secondaries. *ANZ J Surg* 2006;76:575–578.